Status:
UNKNOWN
Single Follicular Dexarelix for LH Suppression During Ovarian Stimulation in Oocyte Donors.
Lead Sponsor:
Assisting Nature
Conditions:
Infertility
Premature Ovarian Failure
Eligibility:
FEMALE
20-34 years
Brief Summary
A randomized prospective study in the evaluation of the long acting GnRH antagonist Degarelix against the classical multidose regime with Ganirelix for LH suppression during the follicular phase of an...
Detailed Description
A randomized prospective study of the use of single dose of the long acting GnRH antagonist Degarelix for ovarian stimulation cycle in oocyte donors: Ovarian stimulation started on cycle Day2 with gon...
Eligibility Criteria
Inclusion
- age 20-34 years;
- body mass index (BMI) 18-29kg/m2;
- regular menstrual cycle of 26-35 days,
- AMH levels age appropriate (≥2.3 ng/ml)
- early follicular- phase serum concentration of FSH within normal limits (1-12 IU/l).
Exclusion
- women with diabetes and other metabolic disease
- women with hereditary genetic diseases;
- women with heart disease, QT prolongation,heart failure
- elevated liver enzymes, liver failure, hepatitis
- women with inflammatory or autoimmune disease
- abnormal karyotype;
- endometriosis stage III/IV;
- history of recurrent miscarriage;
- severe OHSS in a previous stimulation cycle or any contraindication for the use of gonadotrophins.
Key Trial Info
Start Date :
January 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT03861715
Start Date
January 1 2017
End Date
December 1 2021
Last Update
October 8 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assisting Nature
Thessaloniki, Greece, 57001